Clinical Trial Update: Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing intraperitoneal liposomal irinotecan as monotherapy or in combination with recombinant mutant human tumor necrosis factor or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Bevacizumab (bevacizumab)
• Onivyde (irinotecan hydrochloride liposome injection)
• recombinant mutant human tumor necrosis factor

Snippet

Sponsor: Dong sheng Zhang | Conditions: Malignant Ascites | Phase 1, Phase 2 | Status: RECRUITING